Taken together, this evidence suggests that TMS has the potential to modulate plasma BDNF levels and exosomal BDNF concentrations, offering a non-invasive strategy to address both motor and cognitive symptoms in PD. This evidence concerns the gene BDNF and Parkinson disease.